These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis. Virgilio E; Vecchio D; Crespi I; Serino R; Cantello R; Dianzani U; Comi C Mult Scler Relat Disord; 2021 Nov; 56():103231. PubMed ID: 34492629 [TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. Mellergård J; Tisell A; Blystad I; Grönqvist A; Blennow K; Olsson B; Dahle C; Vrethem M; Lundberg P; Ernerudh J Eur J Neurol; 2017 Jan; 24(1):112-121. PubMed ID: 27699930 [TBL] [Abstract][Full Text] [Related]
24. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842 [TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Terzi M; Birinci A; Cetinkaya E; Onar MK Acta Neurol Scand; 2007 May; 115(5):325-30. PubMed ID: 17489943 [TBL] [Abstract][Full Text] [Related]
26. The predictive value of CSF multiple assay in multiple sclerosis: A single center experience. De Fino C; Lucchini M; Lucchetti D; Nociti V; Losavio FA; Bianco A; Colella F; Ricciardi-Tenore C; Sgambato A; Mirabella M Mult Scler Relat Disord; 2019 Oct; 35():176-181. PubMed ID: 31394405 [TBL] [Abstract][Full Text] [Related]
27. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108 [TBL] [Abstract][Full Text] [Related]
28. Can CSF biomarkers predict future MS disease activity and severity? Magliozzi R; Cross AH Mult Scler; 2020 Apr; 26(5):582-590. PubMed ID: 31965889 [TBL] [Abstract][Full Text] [Related]
29. Pilot Study of the Total and Phosphorylated Tau Proteins in Early-Stage Multiple Sclerosis. Masiulienė I; Pampuščenko K; Žemgulytė G; Bilskienė D; Borutaitė V; Balnytė R Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541142 [No Abstract] [Full Text] [Related]
30. Tau protein levels in the cerebrospinal fluid of the patients with multiple sclerosis in an attack period: Low levels of tau protein may have significance, too. Kosehasanogullari G; Ozakbas S; Idiman E Clin Neurol Neurosurg; 2015 Sep; 136():107-9. PubMed ID: 26093227 [TBL] [Abstract][Full Text] [Related]
31. The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: laboratory markers of neurodegenerative diseases. Mares J; Kanovsky P; Herzig R; Stejskal D; Vavrouskova J; Hlustik P; Vranova H; Burval S; Zapletalova J; Pidrman V; Obereigneru R; Suchy A; Vesely J; Podivinsky J; Urbanek K Neurol Sci; 2009 Feb; 30(1):1-7. PubMed ID: 19153649 [TBL] [Abstract][Full Text] [Related]
32. Baló's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures. Jarius S; Würthwein C; Behrens JR; Wanner J; Haas J; Paul F; Wildemann B J Neuroinflammation; 2018 Jan; 15(1):22. PubMed ID: 29347989 [TBL] [Abstract][Full Text] [Related]
33. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Hinsinger G; Galéotti N; Nabholz N; Urbach S; Rigau V; Demattei C; Lehmann S; Camu W; Labauge P; Castelnovo G; Brassat D; Loussouarn D; Salou M; Laplaud D; Casez O; Bockaert J; Marin P; Thouvenot E Mult Scler; 2015 Sep; 21(10):1251-61. PubMed ID: 25698171 [TBL] [Abstract][Full Text] [Related]
34. The Cerebrospinal Fluid in Multiple Sclerosis. Deisenhammer F; Zetterberg H; Fitzner B; Zettl UK Front Immunol; 2019; 10():726. PubMed ID: 31031747 [TBL] [Abstract][Full Text] [Related]
36. Kappa free light chains could predict early disease course in multiple sclerosis. Vecchio D; Crespi I; Virgilio E; Naldi P; Campisi MP; Serino R; Dianzani U; Bellomo G; Cantello R; Comi C Mult Scler Relat Disord; 2019 May; 30():81-84. PubMed ID: 30738877 [TBL] [Abstract][Full Text] [Related]
37. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. Szalardy L; Zadori D; Simu M; Bencsik K; Vecsei L; Klivenyi P J Neurol Sci; 2013 Aug; 331(1-2):38-42. PubMed ID: 23706476 [TBL] [Abstract][Full Text] [Related]
39. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467 [TBL] [Abstract][Full Text] [Related]
40. Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Huang J; Khademi M; Fugger L; Lindhe Ö; Novakova L; Axelsson M; Malmeström C; Constantinescu C; Lycke J; Piehl F; Olsson T; Kockum I Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12952-12960. PubMed ID: 32457139 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]